½ÃÀ庸°í¼­
»óǰÄÚµå
1766191

OTC ¿¬¼Ó Ç÷´ç ¸ð´ÏÅ͸µ ½ÃÀå ±âȸ, ¼ºÀå ÃËÁø¿äÀÎ, »ê¾÷ µ¿Ç⠺м®, ¿¹Ãø(2025-2034³â)

OTC Continuous Glucose Monitoring Market Opportunity, Growth Drivers, Industry Trend Analysis, and Forecast 2025 - 2034

¹ßÇàÀÏ: | ¸®¼­Ä¡»ç: Global Market Insights Inc. | ÆäÀÌÁö Á¤º¸: ¿µ¹® 108 Pages | ¹è¼Û¾È³» : 2-3ÀÏ (¿µ¾÷ÀÏ ±âÁØ)

    
    
    




¡Ø º» »óǰÀº ¿µ¹® ÀÚ·á·Î Çѱ۰ú ¿µ¹® ¸ñÂ÷¿¡ ºÒÀÏÄ¡ÇÏ´Â ³»¿ëÀÌ ÀÖÀ» °æ¿ì ¿µ¹®À» ¿ì¼±ÇÕ´Ï´Ù. Á¤È®ÇÑ °ËÅ並 À§ÇØ ¿µ¹® ¸ñÂ÷¸¦ Âü°íÇØÁֽñ⠹ٶø´Ï´Ù.

¼¼°èÀÇ OTC ¿¬¼Ó Ç÷´ç ¸ð´ÏÅ͸µ ½ÃÀåÀº 2024³â¿¡ 3¾ï 7,070¸¸ ´Þ·¯·Î Æò°¡µÇ¾úÀ¸¸ç, 2034³â¿¡´Â 21¾ï 4,000¸¸ ´Þ·¯¿¡ À̸£¸ç, CAGRÀº 16.9%¸¦ ³ªÅ¸³¾ °ÍÀ¸·Î Àü¸ÁµË´Ï´Ù.

ó¹æÀü¾øÀÌ ±¸ÀÔÇÒ ¼ö ÀÖ´Â OTC CGMÀº ´ç´¢º´ °ü¸®»Ó¸¸ ¾Æ´Ï¶ó º¸´Ù ±¤¹üÀ§ÇÑ °Ç°­ ¸ð´ÏÅ͸µ ÀÀ¿ë ºÐ¾ß¿¡¼­ Á¡Á¡ ´õ Áß¿äÇÑ ¿ªÇÒÀ» ¼öÇàÇϰí ÀÖ½À´Ï´Ù. °³ÀÎÀÇ °Ç°­ Á¤º¸¿¡ ´ëÇÑ ¼ö¿ä°¡ ³ô¾ÆÁü¿¡ µû¶ó, ÀÌ·¯ÇÑ ½Ã½ºÅÛÀº ¿¹¹æ ÇコÄɾ °³Àο¡ ¸ÂÃá ¿µ¾ç °ü¸®¸¦ À§ÇØ ¹Þ¾Æµé¿©Áö°í ÀÖ½À´Ï´Ù. CGMÀº ´õ »ç¿ëÇϱ⠽±°í ´õ ¸¹Àº »ç¶÷µéÀÌ »ç¿ëÇÒ ¼ö ÀÖ½À´Ï´Ù.

OTC ¿¬¼Ó Ç÷´ç ¸ð´ÏÅ͸µ ½ÃÀå-IMG1

Á¦Á¶¾÷ü¿Í µðÁöÅÐ Ç÷§ÆûÀº ¼ÒºñÀÚÀÇ Àü¹ÝÀûÀÎ Á¦Ç° °æÇèÀ» Çâ»ó½Ã۱â À§ÇØ Á¡Á¡ ´õ Çù·ÂÇϰí ÀÖ½À´Ï´Ù. °Ç°­¿¡ ´ëÇÑ ÀλçÀÌÆ®¸¦ ½Ç½Ã°£À¸·Î ÀÌ¿ëÇÒ ¼ö ÀÖ°Ô µÇ¾î, ÀÏÀÏÀÇ ¼±ÅÃÀÌ Æ÷µµ´çÄ¡³ª °Ç°­ Àü¹Ý¿¡ ¾î¶°ÇÑ ¿µÇâÀ» ¹ÌÄ¡´ÂÁö¸¦ ÀÌÇØÇϴµ¥ µµ¿òÀÌ µË´Ï´Ù.

½ÃÀå ¹üÀ§
½ÃÀÛ ¿¬µµ 2024³â
¿¹Ãø ¿¬µµ 2025-2034³â
½ÃÀÛ ±Ý¾× 3¾ï 7,070¸¸ ´Þ·¯
¿¹Ãø ±Ý¾× 21¾ï 4,000¸¸ ´Þ·¯
CAGR 16.9%

¼¾¼­ ºÎ¹®Àº 2024³â¿¡ 3¾ï 2,900¸¸ ´Þ·¯°¡ µÇ¾ú°í, ÃÖ´ëÀÇ Á¡À¯À²À» Â÷ÁöÇß½À´Ï´Ù. ÄÄÆÑÆ®Çϰí, ÄèÀûÇÏ°í »ç¿ëÇϱ⠽¬¿î ¿þ¾î·¯ºí¿¡ÀÇ ±âÈ£ÀÇ °íÁ¶°¡, º¸´Ù Çõ½ÅÀûÀÎ ¼¾¼­ÀÇ °³¹ß¿¡ ¹ÚÂ÷¸¦ °¡Çϰí ÀÖ½À´Ï´Ù. Ãà¼Ò °¡´ÉÇÑ ÀÏ·ºÆ®·Î´Ð½º µîÀÇ ¼±Áø ¼ÒÀç°¡ ³»ÀåµÇ¾î, ÄèÀû¼º°ú ÃøÁ¤ Á¤¹Ðµµ°¡ Çâ»óÇϰí ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ¼¾¼­¸¦ ¿þ¾î·¯ºíÀ̳ª ½º¸¶Æ®Æù°ú ÅëÇÕÇÏ´Â °ÍÀ¸·Î, ¸®¾óŸÀÓÀÇ Á¢¼Ó°ú µ¥ÀÌÅÍ Àü¼ÛÀÌ °¡´ÉÇÏ°Ô µÇ¾î, À¯Àú °æÇèÀÌ Çâ»óÇØ, CGMÀÇ ÀÌ¿ë ¹üÀ§°¡ ³Ð¾îÁý´Ï´Ù.

ÀüÀÚ»ó°Å·¡ ºÎ¹®Àº 2024³â¿¡ 56%ÀÇ Á¡À¯À²À» Â÷ÁöÇß½À´Ï´Ù. ÀÌ ¼ºÀåÀÇ ¿øµ¿·ÂÀÌ µÇ°í ÀÖ´Â °ÍÀº ¼ÒºñÀÚ ÇൿÀÇ º¯È­À̸ç, °Ç°­ ÁöÇâÀÌ ³ôÀº »ç¶÷µéÀº ±âÁ¸ÀÇ ¼Ò¸ÅÁ¡À̳ª ÀÓ»ó Àå¼Ò¸¦ ¿ìȸÇÏ¿© À£´Ï½º ±â±â¸¦ ¿Â¶óÀÎÀ¸·Î ±¸ÀÔÇÏ´Â °ÍÀ» ¼±È£ÇÕ´Ï´Ù. CGM¿¡ ´ëÇÑ Á÷Á¢ ¾×¼¼½º¸¦ Á¦°øÇÏ°í µðÁöÅÐ °Ç°­¿¡ ´ëÇÑ ¿©Çà¿¡ Å« ÀÚÀ²¼ºÀ» Á¦°øÇÕ´Ï´Ù. ÀÌ DTC Á¢±Ù ¹æ½ÄÀ» ÅëÇØ ºê·£µå´Â ¿Â¶óÀΠä³ÎÀ» ÅëÇØ °³ÀÎÈ­µÈ ±³À° ¹× Áö¿øÀ» Á¦°øÇÏ°í °í°´°ú ´õ È¿°úÀûÀ¸·Î Âü¿©ÇÒ ¼ö ÀÖ½À´Ï´Ù.

¹Ì±¹ÀÇ OTC ¿¬¼Ó Ç÷´ç ¸ð´ÏÅ͸µ ½ÃÀåÀº 2034³â±îÁö 11¾ï ´Þ·¯¿¡ À̸¦ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. CGMÀÇ ½ÂÀÎÀ» Æ÷ÇÔÇÑ FDA¿¡ ÀÇÇÑ ±ÔÁ¦ÀÇ Áøº¸´Â ÀÌ·¯ÇÑ ÀåÄ¡ÀÇ º¸±ÞÀ» ´õ¿í ÃËÁøÇϰí ÀÖ½À´Ï´Ù. ±×¸®°í °³ÀÎÈ­µÈ °Ç°­¿¡ ´ëÇÑ ÀλçÀÌÆ®¸¦ ¾òÀ» ¼ö ÀÖ½À´Ï´Ù.

OTC ¿¬¼Ó Ç÷´ç ¸ð´ÏÅ͸µ ½ÃÀå ÁÖ¿ä ±â¾÷À¸·Î´Â Abbott Laboratories, Dexcom, January AI, Levels Health, Limbo(Vitals in View), Nutrisense, Sinocare, Ultrahuman Healthcare, Veri, Zoe µîÀÌ ÀÖ½À´Ï´Ù. OTC ¿¬¼Ó Ç÷´ç ¸ð´ÏÅ͸µ ½ÃÀå¿¡¼­ÀÇ ÇÁ·¹Á𽺸¦ °­È­Çϱâ À§ÇØ °¢ ȸ»ç´Â ¸î °¡Áö Àü·«À» ä¿ëÇϰí ÀÖ½À´Ï´Ù. ³ª»ç¸¦ ¼ÒºñÀÚ¿¡°Ô Á¦°øÇÕ´Ï´Ù. ¶ÇÇÑ ÀüÀÚ»ó°Å·¡·ÎÀÇ ÀüȯÀº ¸¹Àº Á¦Á¶¾÷ü¿¡ ¹Þ¾Æµé¿©Áö°í ÀÖÀ¸¸ç, ¿Â¶óÀΠä³ÎÀ» ÅëÇØ º¸´Ù Æø³ÐÀº ¼ÒºñÀÚÃþ¿¡ Á÷Á¢ µµ´ÞÇÒ ¼ö ÀÖ°Ô µÇ¾î ÀÖ½À´Ï´Ù.

¸ñÂ÷

Á¦1Àå Á¶»ç ¹æ¹ý°ú ¹üÀ§

Á¦2Àå ÁÖ¿ä ¿ä¾à

Á¦3Àå ¾÷°è ÀλçÀÌÆ®

  • »ýÅÂ°è ºÐ¼®
  • ¾÷°è¿¡ ¹ÌÄ¡´Â ¿µÇâ¿äÀÎ
    • ¼ºÀå ÃËÁø¿äÀÎ
      • ½ÅÁø ´ë»ç °Ç°­°ú À£ºù¿¡ ´ëÇÑ ¼ÒºñÀÚÀÇ °ü½É Áõ°¡
      • ¼ÒºñÀÚ Á÷Á¢ ÆÇ¸Å(DTC)°ú ±¸µ¶ ¸ðµ¨ÀÇ È®´ë
      • ±â¼úÀÇ Áøº¸¿Í AI¸¦ Ȱ¿ëÇÑ ÅëÂû
      • ¿¹¹æ ÇコÄɾî¿Í Àå¼öÀÇ µ¿ÇâÀÇ º¯È­
    • ¾÷°èÀÇ ÀáÀçÀû À§Çè ¹× °úÁ¦
      • °í¾×ÀÇ ºñ¿ë°ú ÇÑÁ¤µÈ º¸Çè Àû¿ë
      • ±ÔÁ¦ ¹× µ¥ÀÌÅÍ ÇÁ¶óÀ̹ö½Ã¿¡ ´ëÇÑ ¿ì·Á
  • ¼ºÀå °¡´É¼º ºÐ¼®
  • ±ÔÁ¦ »óȲ
    • ºÏ¹Ì
    • À¯·´
    • ¾Æ½Ã¾ÆÅÂÆò¾ç
    • ¼¼°è ±âŸ Áö¿ª
  • ¼ÒºñÀÚ À¯Çüº° ¼ö·®(2024³â)
  • ±â¼úÀÇ »óȲ
  • ÇâÈÄ ½ÃÀå µ¿Çâ
  • °¸ ºÐ¼®
  • Porter's Five Forces ºÐ¼®
  • PESTEL ºÐ¼®

Á¦4Àå °æÀï ±¸µµ

  • ¼­·Ð
  • ±â¾÷ÀÇ ½ÃÀå Á¡À¯À² ºÐ¼®
    • ¼¾¼­º°
    • Ç÷§Æû/¾Ûº°
  • Áö¿ªº° ±â¾÷ ½ÃÀå ·©Å·
  • ±â¾÷ ¸ÅÆ®¸¯½º ºÐ¼®
  • ÁÖ¿ä ½ÃÀå ±â¾÷ÀÇ °æÀï ºÐ¼®
  • °æÀï Æ÷Áö¼Å´× ¸ÅÆ®¸¯½º
  • Àü·« ´ë½Ãº¸µå

Á¦5Àå ½ÃÀå ÃßÁ¤¡¤¿¹Ãø : ±¸¼º ¿ä¼Òº°(2021-2034³â)

  • ÁÖ¿ä µ¿Çâ
  • ¼¾¼­
  • Ç÷§Æû/¾Û

Á¦6Àå ½ÃÀå ÃßÁ¤¡¤¿¹Ãø : ¼ÒºñÀÚ À¯Çüº°(2021-2034³â)

  • ÁÖ¿ä µ¿Çâ
  • ºñ´ç´¢º´ °Ç°­ ¾ÖÈ£°¡
  • ´ç´¢º´ Àü ´Ü°è ¹× À§Çè¿¡ óÇÑ °³ÀÎ
  • ±âŸ ¼ÒºñÀÚ À¯Çü

Á¦7Àå ½ÃÀå ÃßÁ¤¡¤¿¹Ãø : À¯Åë ä³Îº°(2021-2034³â)

  • ÁÖ¿ä µ¿Çâ
  • º´¿ø ¾à±¹
  • ¼Ò¸Å ¾à±¹
  • ÀüÀÚ»ó°Å·¡

Á¦8Àå ½ÃÀå ÃßÁ¤¡¤¿¹Ãø : Áö¿ªº°(2021-2034³â)

  • ÁÖ¿ä µ¿Çâ
  • ºÏ¹Ì
    • ¹Ì±¹
    • ij³ª´Ù
  • À¯·´
    • µ¶ÀÏ
    • ¿µ±¹
    • ÇÁ¶û½º
    • ÀÌÅ»¸®¾Æ
    • ½ºÆäÀÎ
    • ³×´ú¶õµå
  • ¾Æ½Ã¾ÆÅÂÆò¾ç
    • ÀϺ»
    • Áß±¹
    • Àεµ
    • È£ÁÖ
    • Çѱ¹
  • ¼¼°è ±âŸ Áö¿ª

Á¦9Àå ±â¾÷ ÇÁ·ÎÆÄÀÏ

  • Abbott Laboratories
  • Dexcom
  • January AI
  • Levels Health
  • Limbo(Vitals in View)
  • Nutrisense
  • Sinocare
  • Ultrahuman Healthcare
  • Veri
  • Zoe
KTH 25.07.18

The Global OTC Continuous Glucose Monitoring Market was valued at USD 370.7 million in 2024 and is estimated to grow at a CAGR of 16.9% to reach USD 2.14 billion by 2034. OTC CGMs, which are available for purchase without a prescription, are playing an increasingly significant role not only in managing diabetes but also in broader health monitoring applications. These devices allow consumers to track their glucose levels in real-time, which empowers them to make informed decisions about their diet, exercise, and overall wellness. As the demand for personal health information grows, these systems are being embraced for preventive healthcare and personalized nutrition. With advancements in sensor technology, compact design, longer wearability, and seamless integration with smartphones and AI platforms, OTC CGMs are becoming more user-friendly and accessible to a wider audience.

OTC Continuous Glucose Monitoring Market - IMG1

Manufacturers and digital platforms are increasingly joining forces to improve the overall product experience for consumers. By integrating advanced analytics and offering personalized lifestyle coaching, these collaborations are creating a more engaging and value-driven experience for users. Consumers now have access to insights about their health in real-time, helping them understand how their daily choices impact their glucose levels and overall well-being. This personalized feedback is not just limited to monitoring glucose levels but extends to creating actionable health goals, such as optimizing diet, exercise, and sleep patterns.

Market Scope
Start Year2024
Forecast Year2025-2034
Start Value$370.7 Million
Forecast Value$2.14 Billion
CAGR16.9%

The sensor segment holds the largest share valued at USD 329 million in 2024. The increasing preference for compact, comfortable, and easy-to-use wearables is fueling the development of more innovative sensors. These sensors now incorporate advanced materials such as graphene, flexible polymers, and stretchable electronics to improve comfort and measurement accuracy. The integration of these sensors with wearables and smartphones allows real-time connectivity and data transfer, enhancing the user experience and broadening the scope of CGM usage.

The e-commerce segment held 56% share in 2024. This growth is driven by a shift in consumer behavior, where health-conscious individuals prefer purchasing wellness devices online, bypassing traditional retail and clinical settings. E-commerce platforms offer consumers direct access to OTC CGMs, providing greater autonomy over their digital health journey. This direct-to-consumer approach also enables brands to engage with customers more effectively, offering personalized education and support through online channels.

United States OTC Continuous Glucose Monitoring Market is projected to reach USD 1.1 billion by 2034. The rising interest in preventive health, particularly among non-diabetic individuals, is driving this demand. People are increasingly using CGMs to optimize their diet, exercise, and metabolic performance. Regulatory advancements by the FDA, including approvals for OTC CGMs, are further facilitating the widespread adoption of these devices. The integration of CGMs with smartphones and health apps is also boosting consumer confidence in self-management, enabling users to monitor their glucose levels seamlessly and gain personalized health insights. This trend is supported by the high adoption of digital health tools in the U.S., with consumers increasingly seeking personalized health data.

Key players in the OTC Continuous Glucose Monitoring Market include Abbott Laboratories, Dexcom, January AI, Levels Health, Limbo (Vitals in View), Nutrisense, Sinocare, Ultrahuman Healthcare, Veri, and Zoe. To strengthen their presence in the OTC continuous glucose monitoring market, companies have adopted several strategies. First, they are focusing on enhancing the technology behind their sensors, integrating cutting-edge materials like flexible polymers and stretchable electronics to improve comfort and accuracy. Many companies are also entering strategic partnerships with digital health platforms to provide consumers with additional services, such as AI-powered analytics and personalized coaching. Furthermore, the shift towards e-commerce is being embraced by many manufacturers, allowing them to reach a broader consumer base directly through online channels. By investing in user-friendly designs, providing educational resources, and streamlining the purchase process, these companies aim to increase product adoption and build strong customer loyalty.

Table of Contents

Chapter 1 Methodology and Scope

  • 1.1 Market scope and definitions
  • 1.2 Research design
    • 1.2.1 Research approach
    • 1.2.2 Data collection methods
  • 1.3 Base estimates and calculations
    • 1.3.1 Base year calculation
    • 1.3.2 Key trends for market estimation
  • 1.4 Forecast model
  • 1.5 Primary research and validation
    • 1.5.1 Primary sources
    • 1.5.2 Data mining sources

Chapter 2 Executive Summary

  • 2.1 Industry 3600 synopsis

Chapter 3 Industry Insights

  • 3.1 Industry ecosystem analysis
  • 3.2 Industry impact forces
    • 3.2.1 Growth drivers
      • 3.2.1.1 Rising consumer interest in metabolic health and wellness
      • 3.2.1.2 Expansion of direct-to-consumer (DTC) and subscription models
      • 3.2.1.3 Technological advancements and AI-powered insights
      • 3.2.1.4 Shifts in preventive healthcare and longevity trends
    • 3.2.2 Industry pitfalls and challenges
      • 3.2.2.1 High costs and limited insurance coverage
      • 3.2.2.2 Regulatory and data privacy concerns
  • 3.3 Growth potential analysis
  • 3.4 Regulatory landscape
    • 3.4.1 North America
    • 3.4.2 Europe
    • 3.4.3 Asia Pacific
    • 3.4.4 Rest of the World
  • 3.5 Volume by consumer type, 2024
  • 3.6 Technology landscape
  • 3.7 Future market trends
  • 3.8 Gap analysis
  • 3.9 Porter's analysis
  • 3.10 PESTEL analysis

Chapter 4 Competitive Landscape, 2024

  • 4.1 Introduction
  • 4.2 Company market share analysis
    • 4.2.1 By sensor
    • 4.2.2 By platform/app
  • 4.3 Company market ranking, by region
  • 4.4 Company matrix analysis
  • 4.5 Competitive analysis of major market players
  • 4.6 Competitive positioning matrix
  • 4.7 Strategy dashboard

Chapter 5 Market Estimates and Forecast, By Component, 2021 – 2034 ($ Mn)

  • 5.1 Key trends
  • 5.2 Sensors
  • 5.3 Platforms/Apps

Chapter 6 Market Estimates and Forecast, By Consumer Type, 2021 – 2034 ($ Mn)

  • 6.1 Key trends
  • 6.2 Non-diabetic health enthusiasts
  • 6.3 Pre-diabetic and at-risk individuals
  • 6.4 Other consumer types

Chapter 7 Market Estimates and Forecast, By Distribution Channel, 2021 – 2034 ($ Mn)

  • 7.1 Key trends
  • 7.2 Hospital pharmacies
  • 7.3 Retail pharmacies
  • 7.4 E-commerce

Chapter 8 Market Estimates and Forecast, By Region, 2021 – 2034 ($ Mn)

  • 8.1 Key trends
  • 8.2 North America
    • 8.2.1 U.S.
    • 8.2.2 Canada
  • 8.3 Europe
    • 8.3.1 Germany
    • 8.3.2 UK
    • 8.3.3 France
    • 8.3.4 Italy
    • 8.3.5 Spain
    • 8.3.6 Netherlands
  • 8.4 Asia Pacific
    • 8.4.1 Japan
    • 8.4.2 China
    • 8.4.3 India
    • 8.4.4 Australia
    • 8.4.5 South Korea
  • 8.5 Rest of the World

Chapter 9 Company Profiles

  • 9.1 Abbott Laboratories
  • 9.2 Dexcom
  • 9.3 January AI
  • 9.4 Levels Health
  • 9.5 Limbo (Vitals in View)
  • 9.6 Nutrisense
  • 9.7 Sinocare
  • 9.8 Ultrahuman Healthcare
  • 9.9 Veri
  • 9.10 Zoe
»ùÇà ¿äû ¸ñ·Ï
0 °ÇÀÇ »óǰÀ» ¼±Åà Áß
¸ñ·Ï º¸±â
Àüü»èÁ¦